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We report a case of double primary liver cancer comprising hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC). A 58-year-old Chinese man without obvious liver cirrhosis was diagnosed with multiple
HCC in segment V (SV) and segment VIII (SVIII) of the liver. Preoperative abdominal magnetic resonance imaging
revealed two solid masses in SV and SVIII. We performed hepatic resection of both segments. The tumors in SV and
SVIII were pathologically diagnosed as HCC and ICC, respectively. Immunohistochemically, the HCC in SV was
positive for carcinoembryonic antigen and negative for α-fetoprotein (AFP) and cytokeratin (CK), while the ICC in
SVIII was negative for both AFP and CK. These observations confirmed the diagnosis of double primary liver cancer
(HCC and ICC). Double primary liver cancer is extremely rare. We herein review previous reports of patients with a
histological diagnosis of double primary liver cancer. Based on the findings of this case and the literature review,
we speculate that the imaging findings of double primary hepatic cancer conform to the pathologic findings.
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Hepatocellular carcinoma (HCC) and intrahepatic chol-
angiocarcinoma (ICC) are the two main primary liver
cancers. The occurrence of synchronous double cancers
comprising different primary hepatic tumors is very low.
Only 33 cases of ICC with HCC have been reported [1],
and a survey of previous reports produced only 18 cases
of double primary liver cancers that were synchronously
resected [2]. We herein report a patient who underwent
hepatectomy for double primary liver cancer (HCC and
ICC) without a background of obvious liver cirrhosis.Case presentation
A 58-year-old man presented with a poor appetite and ab-
dominal tenderness in the area of the liver. He was subse-
quently admitted to Northern Jiangsu People’s Hospital in
June 2013 for further examination of a hepatic nodule* Correspondence: bdsno1@hotmail.com
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unless otherwise stated.detected on thoracic computed tomography. His medical
history included cerebral infarction and hypertension, but
he had no history of exposure to any hepatotoxic chemi-
cals or blood transfusions. Physical examination findings
upon admission were normal with the exception of slight
abdominal tenderness in the area of the liver. Laboratory
examination produced the following results: red blood cell
count, 3.22 × 1012/l; hemoglobin, 95 g/l; white blood cell
count, 12.7 × 109/l; albumin, 40.1 g/l; globulin, 18.4 g/l;
total bilirubin, 13.2 μmol/l; and prothrombin time, 13.8 s.
The alanine aminotransferase, aspartate aminotransferase,
and lactate dehydrogenase levels were within their normal
ranges. Hepatitis B virus-related antigen and antibody
were negative with the exception of hepatitis B surface
antibody (578.200 IU/l) and hepatitis B core antibody.
The carbohydrate antigen 19-9, carbohydrate antigen
242, α-fetoprotein, and carcinoembryonic antigen levels
were 331 U/ml, 167.31 U/ml, 9.53 ng/ml, and 3.61 ng/ml,
respectively. Abdominal magnetic resonance imaging iden-
tified two liver tumors: one in segment V (SV, 6 cm in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Abdominal magnetic resonance imaging depicted two isolated tumors. One measured 4.0 cm in diameter and was present in the
left segment of the liver (SVIII, a1). The other measured 6 cm in diameter and was present in the inferior superior segment of the liver (SV, b1).
The larger tumor showed enhancement (b2), and the smaller tumor showed contrast enhancement (a2) in the center of the tumor in the
hepatic arterial phase. In the portal phase, the larger tumor became less dense than the liver parenchyma (b3), but the centrality of the smaller
tumor showed continuous enhancement (a3).
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diameter) of the right lobe (Figure 1). The patient
underwent two systemic partial liver resections and
cholecystectomy. The parenchymal margins were unin-
volved by both tumors. Histopathologic examination of
the liver specimens revealed two types of tumors with
two different histological patterns. The hepatocellular
component of SV exhibited trabecular structures with
large polygonal cells, which were immunohistochemi-
cally positive for carcinoembryonic antigen (Figure 2a).
The cholangiocellular population of SVIII comprised
glandular structures with intraluminal mucin and a dif-
fuse distribution (Figure 2b). The background liver par-
enchyma was noncirrhotic. The patient’s postoperative
course was uneventful, and he was discharged on post-
operative day 15. He was alive without recurrence at
the time of this report. Written informed consent was
obtained from the patient.Figure 2 Light microscopy showing the two tumors (hematoxylin-eos
polygonal cells in a trabecular pattern (a), and the cholangiocarcinoma conDiscussion
Combined HCC and cholangiocarcinoma (cHCC-CC) is
a rare primary liver tumor containing unequivocal ele-
ments of both HCC and ICC. In 1949, Allen and Lisa
[3] first classified cHCC-CC into three groups: type A
(HCC and ICC present at different sites within the same
liver), type B (HCC and ICC present at adjacent sites
and mingling with each other but still recognizable as
distinct tumors), and type C (HCC and ICC components
combined within the same tumor and indistinguishable
as separate entities). Most cHCC-CCs exhibit an HCC
component accompanied by cholangiocarcinoma as a
collision tumor. The reported incidence of cHCC-CC in
one study was only 0.54% among 18,843 pathologically
diagnosed primary liver cancers in Japan [4]. Moreover,
the frequency of synchronous double primary cancers in
the liver is much lower than the frequencies of com-
bined and mixed types [3]. The cellular origin of cHCC-in staining, ×100). The hepatocellular carcinoma comprised
tained mucin-producing glands (b).
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vated hepatic progenitor cells are considered to be in-
volved in carcinogenesis, and at least some cHCC-CCs
are suggested to arise from hepatic progenitor cells [5].
Hepatic progenitor cells have the potential to differenti-
ate into either hepatocytes or cholangiocytes depending
on the damaged cell population. However, this theory
can only explain the growth pattern of types A and B de-
scribed above. Therefore, we speculate that the two
masses composing the double primary hepatic cancer
herein reported arose respectively.
Double primary hepatic cancer is an unusual hepatic
tumor comprising two histologically distinct tumors that
exist simultaneously within the liver. The imaging find-
ings of HCC often exhibit an area of hyperenhancement
in the early phase and hypoenhancement due to washout
of contrast medium in the late phase; otherwise, the ICC
shows peripheral enhancement in the early and late
phases. In the present patient, because both HCC and
ICC occurred in the liver simultaneously, the imaging
findings of these two distinct tumors could be compared
in the same condition. In our patient, slight contrast en-
hancement was observed at the centrality of the mass in
SVIII on magnetic resonance imaging obtained during
the hepatic arterial and portal venous phases; concentric
filling was shown on the delayed images (Figure 1a). In
contrast, the other mass in SV was highly enhanced and
its density gradually decreased in the portal venous and
delayed phases (Figure 1b). We also reviewed four add-
itional studies of double primary liver cancer (HCC and
ICC), and the imaging findings were approximately the
same as those in our patient [1,6-8]. Therefore, we
speculate that the imaging findings of double primary
hepatic cancer conform to the pathologic findings.
Surgery remains the only treatment option offering a po-
tential cure for localized disease, especially in noncirrhotic
patients, although the risk of recurrence may be higher
than that associated with pure HCC or ICC [9]. Lymph
node spread is a well-known mode of dissemination in pa-
tients with ICC. Thus, it can by hypothesized that lymph
node sampling and removal of positive nodes in patients
with cHCC-CC is equally as important as in ICC. Portolani
et al. [10] reviewed 18 patients with cHCC-CC who under-
went surgical resection and reported that nodal metastasis
was a negative prognostic value for both overall and
disease-free survival, with the mean survival duration in
node-positive patients being only 14.7 months compared
with 38.5 months in node-negative patients. Surgery for
HCC usually requires only resection of the liver tumor be-
cause of the low incidence of nodal metastases, while the
presence of cholangiocarcinoma makes lymph node dissec-
tion essential. Wider use of intraoperative frozen biopsy,
especially for lesions not typical for HCC, can be suggested
for the diagnosis and optimal management of cHCC-CC.Previous studies have reported a poorer prognosis for
cHCC-CC than for either HCC or ICC. The prognosis
of combined HCC and ICC has generally been recog-
nized to be poorer than that of ordinary HCC because of
the ability of the combined type to metastasize to many
organs [11]. Cao et al. [12] reported the survival data of
14 patients who had cHCC-CC. The median overall
survival (OS) was 18 months, and the 1-, 3-, and 5-year
OS rates were 60.0%, 28.9%, and 23.1%, respectively.
Multivariate analysis indicated that the ICC tumor size,
presence of lymph mode metastasis, and histological
differentiation of the ICC component were independent
risk factors for OS.
Conclusions
In summary, we have reported a case of double primary
liver cancer (cHCC-CC) confirmed by pathological and
immunohistochemical analyses. Although double primary
liver cancer is rare, it must be considered as a differential
diagnosis of liver tumors. Imaging findings may be helpful
to achieve a correct preoperative diagnosis. If in doubt, in-
traoperative frozen section analysis may be necessary to
select the correct surgical approach.
Consent
Written informed consent was obtained from the patient for
the publication of this case presentation and accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
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